Comparative Pharmacology
Head-to-head clinical analysis: NAGLAZYME versus VIMIZIM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NAGLAZYME versus VIMIZIM.
NAGLAZYME vs VIMIZIM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
NAGLAZYME (galsulfase) is a recombinant form of human N-acetylgalactosamine 4-sulfatase that replaces deficient endogenous enzyme in patients with mucopolysaccharidosis VI (MPS VI). It catalyzes the hydrolysis of N-acetylgalactosamine 4-sulfate groups from glycosaminoglycans (GAGs), reducing GAG accumulation in lysosomes.
VIMIZIM (elosulfase alfa) is a recombinant human N-acetylgalactosamine-6-sulfatase that hydrolyzes the sulfate ester bond at position 6 of N-acetylgalactosamine in chondroitin sulfate and keratan sulfate, thereby reducing glycosaminoglycan (GAG) accumulation in patients with Morquio A syndrome (mucopolysaccharidosis IVA).
1 mg/kg intravenously once weekly.
2 mg/kg administered intravenously once weekly over approximately 4 hours. Pretreat with antihistamines and antipyretics 30-60 minutes prior to infusion.
None Documented
None Documented
Terminal elimination half-life: 6-9 minutes (0.1-0.15 hours); clinically, rapid clearance requires weekly intravenous administration to maintain therapeutic levels.
Terminal elimination half-life approximately 9.8 days (range 7.7–13.8 days) in patients with mucopolysaccharidosis VI (MPS VI). Long half-life supports weekly intravenous dosing.
Renal: 87% of administered dose excreted unchanged in urine within 24 hours; minimal biliary/fecal elimination.
Primarily renal. No specific data on biliary or fecal elimination; as a recombinant enzyme, likely catabolized to peptides and amino acids, with renal excretion of metabolites.
Category C
Category C
Enzyme Replacement Therapy
Enzyme Replacement Therapy